ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0079

Interim Analysis of the COSA Registry: COVID-19 Patients Treated with the Seraph® 100 Microbind® Affinity Filter

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Schmidt, Julius, Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
  • Schmitz, Michael, Stadtisches Klinikum Solingen, Solingen, Nordrhein-Westfalen, Germany
  • Kielstein, Jan T., Academic Teaching Hospital Braunschweig, Braunschweig, Germany
Background

The Seraph®100 Microbind Affinity Blood Filter® is a hemofiltration device that is licensed for pathogen reduction in the blood that received an emergency authorization for the treatment of COVID-19 by the FDA. The aim of this registry was to evaluate safety and efficacy of Seraph 100 treatment for COVID-19 patients.

Methods

This is an online registry in which main patient charcteristics, treatment characteristics and outcome parameters of COVID-19 patients, treated with the Seraph100 can be documented without reimbursement.

Results

Seventy-five treatment sessions in 60 patients from 12 hospitals were documented in the registry (Fig 1). Overall mortality was 42.3%. Adverse events of the Seraph® 100 treatment were reported in 8 (10.6 %) of the 75 treatments. Eight (10.6 %) of all the procedures ended prematurely due to circuit failure. Non-survivor had a higher rate of bacterial superinfection, higher level of inflammatory laboratory markers (procalcitonin and ferritin) and higher d-dimer levels(Fig 2). While predicted mortality according to SOFA score in ICU patients was >80 %, the observed mortality was 47.6 %. In non-ICU patients, 4C score predicted a mortality of 31.4-34.9 % while the observed mortality was 22.2 %.

Conclusion

Seraph 100 treatment was well tolerated and circuit failure rate was significantly lower than reported for KRT in COVID-19 patients. Compared to the calculated mortality, the observed mortality in the registry was lower.